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ABSTRACT
Introduction: Breast cancer can be classified into five subtypes based on variations in the status of three hormonal receptors 
that are responsible for the cancer’s heterogeneity: estrogen receptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor 2 (HER2). These classifications influence the choice of therapies (either neoadjuvant or adjuvant), 
and the range of prognoses, from good (luminal A subtype) to poor (triple-negative cancers).
Objectives: The aim of the study was to compare the serum concentration of selected miRNAs (miRNA-21, miRNA-10b, 
and miRNA-200c) between in two groups of breast cancer patients with differing ER, PR, and HER2 statuses.
Material and methods: The study was performed on two groups of patients. One group (TNBC) consisted of patients with 
triple-negative cancer, and the other group (ER(+)/PR(+)) was comprised of patients with positive ER and PR receptors.
Results: The mean level of miRNA-200c was significantly higher in the ER(+)/PR(+) group than in the TNBC group (p < 0.05). 
No statistically significant difference was found between the two groups with regard to the mean levels of miRNA-21 or 
miRNA-10b.
Conclusions: The level of miRNA-200c was lower in triple-negative patients when compared with the levels in the study’s 
ER/PR positive group.
Key words: miRNA, breast cancer, receptors, biomarker, triple negative
Ginekologia Polska 2018; 89, 8: 414–419
Corresponding author:
Sebastian Niedźwiecki
Department of Surgical Oncology, Medical University of Lodz, Poland
Paderewskiego St. 4, 93–509 Lodz, Poland
tel.: 426895420
e-mail: sebastian.niedzwiecki@umed.lodz.pl
INTRODUCTION
Breast cancer is one of the most often diagnosed malig-
nancies among women in western countries [1]; however, its 
precise etiopathology remains unclear. Most authors agree 
that a crucial role is played by hormones, especially estro-
gen [2], and that the status of the Estrogen receptor (ER), 
Progesterone receptor (PR) and Human Epidermal growth 
factor Receptor 2 (HER2) influence the heterogeneity of the 
disease and form the basis of a five-fold classification of 
the disease (classification of the disease into five molecular 
subtypes) [3]. These classifications also influence the choice 
of therapy (either neo-adjuvant or adjuvant), as well as the 
prognosis of the disease, ranging from good (luminal A sub-
type) to poor (triple-negative cancers) [4, 5]. More precise 
methods of molecular diagnosis will be necessary in future 
breast cancer therapy to allow for more personalized treat-
ments, because, currently, there are no sensitive and specific 
non-invasive biomarkers for the diagnosis of the status of 
the receptors (ER, PR and HER2) or of the molecular pattern 
of the breast cancer.
A microRNA (miRNA) is a small non-coding RNA mol-
ecule. These molecules play a role in regulating gene expres-
sion at the post-transcriptional level [6]. Although they are 
short (20–24 nucleotides), miRNA molecules are involved in 
the regulation of crucial cell processes such as proliferation, 
differentiation and apoptosis [7]. Many of the miRNA mol-
ecules are known to be important in the pathogenesis and 
diagnosis of breast cancer [8]. For instance, miRNA-21 and 
415
Sebastian Niedźwiecki et al., Serum miRNAs in triple-negative breast cancer 
www. journals.viamedica.pl/ginekologia_polska
miRNA-10b are oncogenic types of miRNA, and the former 
is over-expressed in breast cancer tissue [9], while the latter 
influences the migration and invasion of cancer cells [10]. 
Further, the downregulation of miRNA-200c facilitates cell 
migration and the creation of remote metastases [11]. 
Some authors postulate a relationship between miRNA 
molecules and the expression of ER, PR or HER2 receptors in 
breast cancer tissue. A study of miRNA-21 and miRNA-10b 
found a correlation between the expression of the miRNAs 
and the presence of the HER2 receptor in breast cancer 
tissue [12]. Yan et al. observed that upregulation of miR-
NA-21 was significantly correlated with the status of the 
PR receptor [13]; however, Gao et al. reported a lack of any 
correlation between miRNA-21 levels and the status of either 
of the ER or PR receptors [14]. 
Objectives
In our study we aimed to perform comparisons between 
the serum concentrations of selected miRNAs (miRNA-21, 
miRNA-10b and miRNA-200c) in two groups of breast cancer 
patients with differing ER, PR and HER2 receptor statuses.
MATERIAL AND METHODS
A total of 46 female patients with breast cancer and 
who had undergone surgery at the Department of Surgical 
Oncology, of the Medical University of Lodz, Poland, during 
the period of March to December 2014, enrolled in our study. 
The ages of the patients ranged from 38 to 72 years, with 
a mean age of 56.44.
All patients were diagnosed by mammography and 
ultrasonography. In addition, every case of breast cancer 
was confirmed by histopathological diagnosis of a specimen 
obtained by core-needle biopsy.
The histologic diagnosis was based on the World Health 
Organization criteria, and pathologic staging was performed 
according to the tumor, node, metastasis classification sys-
tem revisions of 2002 [15].
No patients displayed clinical symptoms of axillary 
lymph node metastases. None of the patients had received 
any treatment before admission to the department. All 
patients had indications for primary surgical treatment of 
breast cancer. 
The final, postoperative histopathological diagnosis re-
vealed invasive ductal breast cancer in each patient. For the 
purposes of our study, the patients were divided into two 
study groups: Triple-Negative Breast Cancer (TNBC) patients, 
and Positive ER and PR receptor (ER(+)/PR(+))patients. Re-
ceptor status was determined by a dedicated pathologist. 
Blood samples were collected from the antecubital 
vein one day before surgery. The samples were centrifuged 
within 15 minutes with a gravitation force of 1500 g, and the 
serum was aliquoted and stored at –80°C. The project was 
approved by the Ethical Committee for Scientific Studies of 
the Medical University of Lodz, Poland.
Isolation of miRNAs 
The total RNA including the circulating miRNA was isolat-
ed from the blood serum using an miRNeasy Mini Kit (Qiagen). 
To ensure complete dissociation of nucleoprotein complexes, 
1 ml of QIAzol Lysis Reagent was added to 0.2 ml of serum, 
mixed by vigorous shaking for 10 s, and incubated for five 
minutes at RT. All samples were supplemented with 5 pg 
Caenorhabditis elegans synthetic miRNA-39 (cel-miRNA-39) 
which was used for normalization of the RNA preparation. 
Aqueous and organic phase separation was achieved by 
addition of 200 μl of chloroform. The mixture was vigorously 
shaken for 15 s, incubated for 3 min at RT and centrifuged 
at 14,000 g for 15 min at 4°C. Total RNA was precipitated 
from the upper (aqueous) phase by adding 1.5 volumes of 
100% ethanol. Purification of the total RNA extracted was 
performed with miRNeasy columns (Qiagen) according to 
the manufacturer’s instructions. RNA was eluted from the 
Qiagen columns in 30 μl of RNase-free water.
MicroRNA (miRNA) quantification 
Reverse transcription was performed using the 
TaqMan miRNA Reverse Transcription Kit and miRNA-specif-
ic stem-loop primers (Applied Biosystems) according to the 
manufacturer’s protocols. Real-time PCR reactions were carried 
out on 5 μl of total RNA eluate using standard TaqMan® Mi-
croRNA Assays (Applied Biosystems) as a control: hsa-miR-10b 
(Assay ID 002218), hsa-miR-21 (Assay ID 000397), hsa-miR-200c 
(Assay ID 002300), and cel-miR-39 (Assay ID: 000200). The 
reactions were run in duplicate, in volumes of 20 μl using 
10 μl TaqMan Universal PCR Master Mix, 1 μl miRNA-specific 
primer/probe mix, and 1.33 μl RT product. The reactions were 
incubated in a 96-well plate at 95°C for 10 min, followed by 
40 cycles of 95°C for 15 s and 60°C for 1 min. Real-Time PCR 
analysis was applied. Raw Ct was used for analysis.
Statistical analysis
We used Statistica software (version 10.0) for the sta-
tistical analysis of our data. The results were presented as 
mean values. The Mann-Whitney and Kruskal-Wallis tests 
were used to compare the measured parameters. Pearson’s 
linear correlation analysis was used to identify any inde-
pendent relationships between serum miRNA concentra-
tions. Normal distribution of the values was confirmed using 
the Kolmogorow-Smirnow test with the Lillefors test. The 
values were statistically significant at p < 0.05.
RESULTS
In total, 46 female patients were included in our study. 
The Mean age at diagnosis was 56.44 years (the age range 
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was 38–72). To determine the relationship between the 
serum concentrations of selected miRNAs (miRNA-21, miR-
NA-10b and miRNA-200c) and the ER, PR and HER2 status 
of the breast cancer patients, two groups of breast can-
cer patients were formed: one with triple-negative cancer 
(TNBC) and the other with positive ER and PR receptors 
(ER(+)/PR(+)). The characterization and distribution of the 
two groups is presented in Table 1. No significant differences 
were observed between the groups with regard to age 
(p = 0.321), BMI (p = 0.56), or menopausal status (p = 0.393). 
No significant differences were found in other epidemiologi-
cal data; nor were there significant difference between the 
study groups in regard to the incidence of hypertension 
(p = 0.54), diabetes (p = 0.311), or ischaemic heart disease 
(p = 0.062). However, the tumors observed in the TNBC 
group were characterized by significantly lower differentia-
tion than in the other group. 
According to the miRNA validation, the mean circulating 
level (raw Ct) of miRNA-21 was 26.5 in the TNBC group and 
26.05 in the ER(+)/PR(+) group (Fig. 1), which was not signifi-
cantly different (p = 0.447, Pearson’s linear correlation analy-
sis). Similarly, no significant difference was found between 
the two groups’ mean levels (raw Ct) of miRNA-10b: 33.5 in 
TNBC and 33.43 in ER(+)/PR(+) (Fig. 2) (p = 0.397, Pearson’s 
linear correlation analysis). However, the expression level 
(raw Ct) of miRNA-200c was found to be significantly higher 
in the ER(+)/PR(+) group (38.78) compared with the TNBC 
Table 1. Clinicopathological characteristics of patients with triple-negative (TNBC) and with ER-positive and PR-positive receptors (ER(+)/ 
/PR(+)) breast cancer
TNBC ER(+)/PR(+) p Value
Mean age (years) 56.48 52.23 p = 0.321
BMI 26.21 26.78 p = 0.56
Menopausal status p = 0.393
Pre-menopause 1 (11.11%) 3 (8.10%)
Post-menopause 8 (88.88%) 34 (91.89%)
Diabetes 4 (44.44%) 12 (32.43%) p = 0.311
Ischaemic heart disease 4 (44.44%) 9 (24.32%)  p = 0.062
Hypertension 3 (33.33%) 7 (18.91%) p = 0.54
Tumor
T1 2 (22.22%) 15 (40.50%) p = 0.43
T2 7 (77.77%) 22 (59.45%) p = 0.387
T3 0 0
T4 0 0
Grading
G1 1 (11.11%) 18 (48.64%) p < 0.05
G2 2 (22.22%) 15 (40.54%) p = 0.361
G3 6 (66.66%) 4 (10.81%) p < 0.05
TNBC — patients with triple-negative breast cancer; ER(+)/PR(+) — patients with positive ER and PR receptors
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Figure 1. Expression of miRNA-21 (mean ± standard deviation) in serum 
of breast cancer patients (p = 0.447). Group 1 — patients with triple-
negative cancer, Group 2 — patients with positive ER and PR receptors
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Figure 2. Expression of miRNA-10b (mean ± standard deviation) in serum 
of breast cancer patients (p = 0.397). Group 1 — patients with triple-
negative cancer, Group 2 — patients with positive ER and PR receptors
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group (20.13), this being a fold change of approximately 
1.92 (p < 0.05, Pearson’s linear correlation analysis) (Fig. 3). 
DISCUSSION
In the present study, we researched the serum levels of 
miRNAs (miRNA-21, miRNA-10b and miRNA200c) to identify 
possible interactions in triple-negative primary breast can-
cers. We compared the serum levels of these miRNAs between 
one group of patients with triple negative cancer and another 
group of patients with ER/PR-positive breast cancer. The broad 
contribution of miRNAs to the oncogenesis of breast cancer 
suggests that they may act as new diagnostic or prognostic 
factors, as well as therapeutic targets. The chosen miRNAs were 
known to be dysregulated in breast cancer tissue and had 
previously been confirmed in in vitro studies to play a role in 
the etiopathogenesis of breast cancer at the molecular level.
The relationship between miRNAs and ER, PR and HER2 re-
ceptors expression remains unclear. The few papers that have 
examined the aforementioned relationship have reported 
contrary results. Wang et al. postulated miRNAs as a biomarker 
of the grading and prognosis of breast cancer due to the 
relative expression of miRNA-21 correlated with hormone 
receptor expression [16]. However, while Heneghan et al. 
report up-regulation of circulating miRNA-21 and miRNA-10b 
in patients with ER-negative breast tumors [17], other authors 
have found higher miRNA-21 levels in biopsy specimens in 
ER-positive breast cancer tissue [18]. Another study based 
on a large population of cancer patients also identified high 
miRNA-21 expression in ER-negative tissue [19]. Ioro et al. 
report that high miRNA-21 expression appears to depend 
not only on ER status but also on tumor diameter, and that 
miRNA-21 expression was higher in T2/T3 than in T1 tumors 
[20]. The tumor diameters were more homogeneous in our 
study group (only T1 and T2). In vitro research has found that 
changes in miRNA-21 expression could be responsible for hor-
monal therapy resistance [19]. Heneghan et al. postulate the 
use of miRNA as a marker of breast cancer progression [21].
Hagrass et al. report higher concentrations of circulating 
miRNA-10b in patients with ER-negative breast cancer [22]. 
Radojicic et al. report miRNA dysregulation in triple-negative 
breast cancer: miRNA-21 was up-regulated in triple-negative 
breast cancer tissue compared with ER/PR-positive tissue 
and healthy controls; whereas miR-10b and other selected 
miRNAs were significantly under-expressed. In addition, 
miRNA-21 dysregulation was associated with worse patient 
overall survival [23].
Although it is commonly stated that miRNA-21 ex-
pression is higher in breast cancer tissue as well as in tri-
ple-negative cancers, this was not demonstrated in our 
study: the group of patients with triple-negative cancer 
demonstrated no significant difference in the serum level 
of miRNA-21. However, due to the small number of pub-
lications examining this issue, the nature of the level of 
miRNA-21 in blood serum remains open to question. Other 
factors may influence the measurement of miRNA-21 in 
serum. Abrahamsson et al. reported miRNA-21 serum levels 
to be dependent on hormonal status, with miRNA-21 levels 
being significantly lower in postmenopausal women [24]. 
Unfortunately, due to the small number of patients in our 
study group, it was not possible to confirm this relationship.
MicroRNA-10b is reported in the literature to be 
down-regulated in triple-negative breast cancer cases com-
pared with normal tissue [23]. However, some authors report 
a higher level of circulating miRNA-10b in patients with the 
ER-negative disease [25]. MicroRNA-10b, along with other 
miRNAs (miR-21, miR-31, miR-125b, miR-130a-3p, miR-155, 
miR-181a, miR-181b, miR-183, miR-195, and miR-451a) has 
been proposed as a biomarker for separating triple-negative 
breast cancer from normal breast tissue [26]. However, our 
findings indicate that miRNA-10b levels did not differ signifi-
cantly between the triple-negative breast cancer group and 
the receptor positive group. Many studies revealed miR-10b 
expression to be greater in metastatic breast cancer due to 
its role in the regulation of cell migration and invasion [27]. 
Both of our examined groups contained metastatic patients, 
which can influence the serum level of miRNA-10b. Inter-
estingly, Anfossi et al. report increased miRNA-10b serum 
levels in metastatic HER2-positive patients compared with 
metastatic HER2-negative patients [28].
Our results confirm that the miR-200c level is downregu-
lated in patients with triple-negative breast cancers [12]. 
Another study identified lower miRNA-200c in triple-nega-
tive breast cancer with metastasis: a more precise analysis 
showed that this dysregulation resulted from the influence 
of negative receptor expression on miRNA-200c tissue. The 
sensitivity and specificity of miRNA-200c as a marker in 
predicting metastasis among patients with triple-negative 
breast cancer was found, in that study, to be 87.5% and 
81.3% respectively [29]. 
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Figure 3. Expression of miRNA-200c (mean ± standard deviation) in 
serum of breast cancer patients (p < 0.05). Group 1 — patients with triple-
negative cancer, Group 2 — patients with positive ER and PR receptors
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Unfortunately, the small number of studies on the se-
rum level of miRNA-200c among patients with triple-neg-
ative breast cancer prevents any detailed comparison. 
However, miRNA-200c is part of large miRNA family which 
also includes miRNA-200a, miRNA-200b, miRNA-141 and 
miRNA-429. miRNA-200b was researched as a biomarker 
in breast core needle biopsy. Authors did not state any cor-
relation between miRNA-200b and tissue expression of PR, 
ER and HER2 [30].
Triple-negative breast cancer is a highly heterogeneous 
disease. The molecular heterogeneity causes difficulties in cre-
ating appropriate targeted therapies for triple-negative breast 
cancer patients. However, miRNAs could act as biomarkers for 
indicating therapeutic targets for systemic treatment.
The term for the conversion of hormone receptor status 
in breast cancer is well known. Namely, it is defined as the 
difference in the expression of hormone receptors between 
the primary tumor and metastases and occurs in 18–54% of 
patients [31]. Determining circulating miRNA -200c could be 
used as a test prior to the decision on how to treat breast 
cancer metastases.
CONCLUSIONS
Circulating miRNA-200c was lower in the triple-negative 
group of patients compared with the ER/PR positive group. 
More studies on large numbers of patients are needed to 
explain the relationship between miRNA-200c serum levels 
and hormone receptor expression in breast cancer tissue.
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